225 related articles for article (PubMed ID: 33854974)
1. Myeloid-Derived Suppressor Cells in Immune Microenvironment Promote Progression of Esophagogastric Junction Adenocarcinoma.
Wang Y; Sun H; Zhu N; Wu X; Sui Z; Gong L; Yu Z
Front Oncol; 2021; 11():640080. PubMed ID: 33854974
[TBL] [Abstract][Full Text] [Related]
2. RNA-Seq Analysis of Colorectal Tumor-Infiltrating Myeloid-Derived Suppressor Cell Subsets Revealed Gene Signatures of Poor Prognosis.
Saleh R; Sasidharan Nair V; Al-Dhaheri M; Khawar M; Abu Nada M; Alajez NM; Elkord E
Front Oncol; 2020; 10():604906. PubMed ID: 33312958
[TBL] [Abstract][Full Text] [Related]
3. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.
Okła K; Czerwonka A; Wawruszak A; Bobiński M; Bilska M; Tarkowski R; Bednarek W; Wertel I; Kotarski J
Front Immunol; 2019; 10():691. PubMed ID: 31001284
[TBL] [Abstract][Full Text] [Related]
4. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
5. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer.
Sasidharan Nair V; Saleh R; Toor SM; Taha RZ; Ahmed AA; Kurer MA; Murshed K; Alajez NM; Abu Nada M; Elkord E
Clin Epigenetics; 2020 Jan; 12(1):13. PubMed ID: 31941522
[TBL] [Abstract][Full Text] [Related]
7. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
8. Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer.
Wen J; Huang G; Liu S; Wan J; Wang X; Zhu Y; Kaliney W; Zhang C; Cheng L; Wen X; Lu X
J Pathol Clin Res; 2020 Jul; 6(3):171-177. PubMed ID: 32149481
[TBL] [Abstract][Full Text] [Related]
9. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
10. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
[TBL] [Abstract][Full Text] [Related]
11. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
Yamauchi Y; Safi S; Blattner C; Rathinasamy A; Umansky L; Juenger S; Warth A; Eichhorn M; Muley T; Herth FJF; Dienemann H; Platten M; Beckhove P; Utikal J; Hoffmann H; Umansky V
Am J Respir Crit Care Med; 2018 Sep; 198(6):777-787. PubMed ID: 29617574
[TBL] [Abstract][Full Text] [Related]
12. Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis.
Qin G; Lian J; Huang L; Zhao Q; Liu S; Zhang Z; Chen X; Yue D; Li L; Li F; Wang L; Umansky V; Zhang B; Yang S; Zhang Y
Oncoimmunology; 2018; 7(7):e1442167. PubMed ID: 29900050
[No Abstract] [Full Text] [Related]
13. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
14. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
[TBL] [Abstract][Full Text] [Related]
15. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients.
Sasidharan Nair V; Saleh R; Toor SM; Alajez NM; Elkord E
Front Oncol; 2020; 10():1530. PubMed ID: 32984004
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
18. Comparative single-cell analysis reveals heterogeneous immune landscapes in adenocarcinoma of the esophagogastric junction and gastric adenocarcinoma.
Chen J; Huang Q; Li YQ; Li Z; Zheng J; Hu W; Yang Y; Wu D; Bei JX; Gu B; Wang J; Li Y
Cell Death Dis; 2024 Jan; 15(1):15. PubMed ID: 38182569
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
